SCHEMBL10271105

SCHEMBL10271105

Cc1cccc2oc(-c3ccc(NC4CCOCC4)c(N)c3)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
HPGD P15428 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
PIK3CD O00329 2/20 0.38
TP53 P04637 2/20 0.38
ALOX12 P18054 1/20 0.38
HAVCR2 Q8TDQ0 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CEPT1 Q9Y6K0 1/20 0.37
GAK O14976 1/20 0.36
OPRK1 P41145 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
AGPAT2 O15120 1/20 0.34
PIK3CA P42336 2/20 0.34
MAPK1 P28482 1/20 0.34
ALDH1A1 P00352 2/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2688593 0.83 NPC1 (0.48) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL23558137 0.78 NPC1 (0.44) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL2687845 0.76 SMN1; SMN2 (0.47) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL2688693 0.75 NPC1 (0.52) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL25857096 0.75 NPC1 (0.42) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL31154363 0.74 NPC1 (0.63) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL10219511 0.73 NPC1 (0.49) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL15673635 0.72 CEPT1 (0.36) NPC1RAB9AHPGDSMN1; SMN2PIK3CD
SCHEMBL31154233 0.71 NPC1 (0.49) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL15693816 0.71 NPC1 (0.47) NPC1RAB9AHPGDSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
EP-2436683-B1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL CO (JP) 2014-05-14 EP disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 NPC1 525/4885RAB9A 2914/4885HPGD 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.